Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401744 | 0.87 | PKM (0.37) | PKMGAARAB9ASMN1; SMN2HDAC4 | |
| SCHEMBL12404698 | 0.85 | NR1I2 (0.38) | PKMHDAC4HDAC1NR1I2 | |
| SCHEMBL12401538 | 0.85 | SMN1; SMN2 (0.36) | GAARAB9ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL12401540 | 0.85 | SMN1; SMN2 (0.36) | GAARAB9ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL15368937 | 0.83 | RAB9A (0.36) | PKMGAARAB9ASMN1; SMN2 | |
| SCHEMBL12401723 | 0.80 | HDAC4 (0.33) | GAARAB9ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL12401717 | 0.79 | SMN1; SMN2 (0.43) | GAARAB9ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL12401730 | 0.79 | CAPN1 (0.42) | GAARAB9ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL12401552 | 0.79 | KMT2A (0.36) | GAARAB9ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL12401551 | 0.79 | KMT2A (0.36) | GAARAB9ASMN1; SMN2HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | PKM 3394/4885GAA 773/4885RAB9A 2004/4885 |
| US-20100272681-A1 | Inhibitors of Serine Proteases | SERPINB1, PRSS1, SPINT2 | PKM 3929/4885GAA 751/4885RAB9A 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.